Skip to content
2000
Volume 26, Issue 16
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.

© Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867325666180201095743
2019-05-01
2025-11-09

  • From This Site

    /content/journals/cmc/10.2174/0929867325666180201095743
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867325666180201095743
Loading

  • Article Type:     Review Article
Keyword(s): gene therapy; immunity; inflammation; initial combination therapy; macitentan; metabolism; pulmonary arterial denervation; Pulmonary arterial hypertension; riociguat; selexipag; serotonin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test